Covid-19 roundup: Pfizer says Xeljanz reduced death and lung failure in hospitalized Covid-19 patients; US halts distribution of Eli Lilly’s mAb combo to Rhode Island due to variants
In addition to its ultra-effective mRNA vaccine, Pfizer believes it could have another weapon to fight the Covid-19 pandemic.
The company reported on Wednesday that its rheumatoid arthritis blockbuster Xeljanz significantly lowered the incidence of death or respiratory failure in hospitalized patients with Covid-19 pneumonia in Brazil.
“To effectively combat the COVID-19 pandemic, there remains a critical need for multiple therapeutic options to treat patients who have contracted the virus,” Tamas Koncz, CMO of Pfizer Inflammation & Immunology, said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.